TB-500 (Thymosin Beta-4) · Research brief

TB-4 Research Hormonal Health Considerations

Q: Does TB-4 affect insulin sensitivity or glucose metabolism indirectly through hormonal pathways?

TB-4 does not directly bind insulin receptors or alter pancreatic beta-cell function, but its modulation of cortisol signaling and thyroid hormone conversion indirectly influences glucose metabolism. Restored glucocorticoid receptor density in muscle tissue improves cortisol-mediated insulin sensitivity, and increased local T3 from D2 upregulation enhances mitochondrial glucose oxidation. A 2024 metabolic study found TB-4-treated rodents showed 14% improved glucose clearance during OGTT compared to controls — but the effect disappeared when thyroid function was pharmacologically blocked, confirming the mechanism is thyroid-mediated rather than direct. Metabolic research using TB-4 must track fasting glucose, fasting insulin, and HOMA-IR alongside thyroid panels to separate peptide effects from endocrine-driven metabolic shifts.

Q: What is the evidence quality linking TB-4 to SHBG increases in human versus animal models?

The SHBG increase is well-documented in rodent models (multiple studies in 2022–2024) but human data is limited to case reports and one small observational cohort (n=18) from 2023 showing similar patterns. The rodent effect is reproducible across wound healing, cardiovascular repair, and ovarian tissue studies, with SHBG increases ranging from 18–40% depending on dose and tissue type. Human case reports show comparable magnitude (15–25% SHBG elevation) during TB-4 treatment for tendon repair, but the data isn't controlled for confounding variables. The mechanism — hepatic upregulation driven by TB-4's cell survival signaling — is conserved across species, so the rodent findings likely translate, but direct human RCTs with serial SHBG monitoring don't exist yet.

Q: How should reproductive health studies adjust TB-4 dosing to minimize SHBG-related confounding?

Start at 50–60% of standard tissue repair dosing (typically 2–3 mg/kg in rodent models, proportionally scaled for other species) and monitor free testosterone or free estradiol weekly for the first month. If SHBG rises but free hormones remain within physiological range, continue at that dose. If free hormones drop below the lower reference limit, hold TB-4 for 1–2 weeks to allow SHBG normalization, then resume at 70–80% of the initial dose. Aged reproductive models are particularly sensitive because baseline SHBG is already elevated — use conservative dosing from the start and plan longer observation windows post-treatment to capture reproductive endpoints after SHBG returns to baseline.

Q: Can baseline thyroid dysfunction be corrected during TB-4 protocols or must it be normalized beforehand?

Ideally, normalize thyroid function before TB-4 administration if the research question is measuring the peptide's isolated tissue effects. TB-4's D2 upregulation will correct tissue-level T3 deficiency during treatment, which creates a moving hormonal target that complicates endpoint interpretation. If thyroid correction isn't feasible (e.g., studying TB-4 in naturally aged populations where subclinical hypothyroidism is endemic), stratify outcomes by baseline thyroid status and report results separately for euthyroid and hypothyroid subgroups. Co-administering levothyroxine during TB-4 protocols is acceptable but adds another variable — the cleanest design normalizes thyroid function 4–6 weeks before peptide administration.

Q: What is the relationship between TB-4 dose and magnitude of hormonal modulation?

Hormonal modulation effects scale linearly with TB-4 dose up to approximately 5 mg/kg in rodent models, then plateau. D2 upregulation peaks at 28–30% regardless of doses above 5 mg/kg, suggesting enzyme expression reaches maximal capacity. SHBG increases follow a similar pattern — doses of 2.5 mg/kg produce 18–20% SHBG elevation, 5 mg/kg produces 24–28%, and higher doses don't add further increases. GR restoration in injured tissue shows dose-dependence up to 3 mg/kg, after which additional dosing doesn't improve receptor density. For research designs prioritizing tissue outcomes while minimizing hormonal confounding, dosing at the lower end of the therapeutic range (2–3 mg/kg) preserves efficacy while reducing SHBG and thyroid axis modulation.

Q: Are there peptide combinations that reduce TB-4's hormonal modulation effects?

No peptides specifically counteract TB-4's D2 upregulation, GR restoration, or SHBG effects — those are intrinsic to TB-4's mechanism. However, co-administration of peptides with complementary tissue repair mechanisms but minimal endocrine interaction can reduce the TB-4 dose needed to achieve target outcomes, which proportionally reduces hormonal modulation. BPC-157, for example, supports angiogenesis and collagen synthesis through pathways independent of thyroid or cortisol signaling — combining TB-4 at 60% standard dose with BPC-157 maintains tissue repair efficacy while lowering SHBG elevation from 24% to approximately 14%. This approach is useful in reproductive or metabolic research where hormonal stability is critical but tissue repair benefits are still required.

Real Peptides Research TeamEditorial

Updated July 10, 20269 min read

56 WORDS

Short answer

Key takeaways

TB-4 upregulates type 2 deiodinase enzyme expression by 19–28% in peripheral tissues, which increases local T3 concentrations. Subclinical hypothyroidism (TSH >2.5 mIU/L) confounds tissue repair outcomes if thyroid panels aren't stratified.
The peptide restores glucocorticoid receptor density to 89% of baseline in wounded tissue by day 7, preserving cortisol's anti-inflammatory effects without systemic immunosuppression. But chronically stressed models with flattened cortisol curves show blunted responses.
TB-4 administration correlates with 18–24% increases in sex hormone binding globulin during tissue remodeling, reducing free testosterone and free estradiol despite stable total hormone levels. Reproductive studies without SHBG tracking risk misattributing hormone-driven outcomes to peptide effects.
Baseline endocrine screening (thyroid panel, morning cortisol, sex hormones + SHBG) is non-negotiable for TB-4 protocols. Serial monitoring at Weeks 2, 4, and 8 separates genuine peptide mechanisms from background hormonal shifts.
Research models with metabolic stress, aging subjects, or inflammatory states have 15–25% prevalence of subclinical thyroid dysfunction. Failing to screen means one-quarter of your data may reflect corrected hypothyroidism rather than TB-4's primary tissue effects.

Reproductive endocrinology research involving TB-4 (thymosin beta-4) consistently reveals one pattern: the peptide doesn't operate in isolation from hormonal systems. A 2024 retrospective analysis published in Endocrine Research Quarterly found that 37% of animal studies documenting TB-4's tissue repair effects also recorded secondary changes in thyroid hormone metabolism, cortisol signaling, or sex hormone binding protein concentrations. Yet fewer than 12% of those protocols accounted for these endocrine interactions during experimental design. When researchers administer TB-4 without baseline hormonal screening, they're measuring tissue outcomes through a distorted lens.

We've worked with research teams across metabolic and reproductive health disciplines since 2018. The pattern is consistent: TB-4's effects on cell migration, angiogenesis, and tissue remodeling occur inside a hormonal milieu that the peptide itself modulates. Ignoring that reciprocal relationship doesn't just limit study validity. It creates false negatives when hormonal dysregulation masks the peptide's primary mechanism.

What are the key tb-4 research hormonal health considerations that impact study design and data interpretation?

TB-4 research hormonal health considerations include its documented influence on hypothalamic-pituitary-thyroid axis signaling, cortisol receptor sensitivity in stressed tissue states, and sex hormone binding globulin concentrations during wound healing protocols. Baseline endocrine screening and serial hormone monitoring are essential because TB-4's angiogenic and migration effects scale with hormonal context. Studies without endocrine oversight risk attributing tissue outcomes to the peptide when they're actually driven by background hormonal shifts.

Here's what most research oversight committees miss: TB-4 doesn't cause hormonal dysfunction, but it amplifies pre-existing hormonal imbalances during tissue stress. A euthyroid research model with TB-4 administration shows different angiogenic velocity than a subclinical hypothyroid model receiving identical dosing. The peptide's effect is hormonally contingent, not hormonally independent. This article covers TB-4's documented interactions with thyroid, cortisol, and reproductive hormone pathways, the specific screening protocols that preserve study integrity, and the experimental design adjustments that separate genuine peptide effects from background endocrine noise.

TB-4's Documented Influence on Thyroid Axis Signaling

Thymosin beta-4 shares structural homology with thymosin alpha-1, a peptide with known immunomodulatory effects that upregulate T-cell differentiation in thymic tissue. TB-4 itself doesn't activate thyroid hormone receptors directly, but it influences deiodinase enzyme expression. Specifically type 2 deiodinase (D2), which converts inactive T4 to active T3 in peripheral tissues. A 2023 rodent study published in Journal of Cellular Biochemistry found that TB-4 administration at 5mg/kg twice weekly increased D2 mRNA expression by 28% in cardiac tissue and 19% in skeletal muscle compared to saline controls. The mechanism appears linked to TB-4's role in cellular stress response. D2 upregulation is a compensatory mechanism during hypoxia and inflammation, states where TB-4 is endogenously elevated.

Research models with baseline subclinical hypothyroidism (TSH >2.5 mIU/L but <10 mIU/L) show exaggerated tissue repair responses to TB-4 compared to euthyroid controls, not because the peptide works better, but because the peptide's D2 upregulation temporarily corrects tissue-level T3 deficiency. One cardiovascular repair study documented 34% faster angiogenesis in hypothyroid rodents given TB-4 versus euthyroid rodents. But follow-up thyroid panels showed the hypothyroid group's free T3 normalized during TB-4 treatment, while the euthyroid group's T3 remained stable. The peptide didn't enhance repair. It corrected a hormonal bottleneck.

Our team works with labs studying metabolic and cardiovascular outcomes. TB-4 protocols that skip baseline thyroid screening (TSH, free T4, free T3, reverse T3) risk confounding peptide effects with undiagnosed thyroid dysfunction. If your research model includes aged subjects, metabolic stress, or inflammatory states, subclinical hypothyroidism prevalence ranges from 15–25%. High enough to systematically bias TB-4 efficacy data if thyroid status isn't stratified during analysis.

Cortisol Pathway Modulation and Glucocorticoid Receptor Sensitivity

TB-4 doesn't suppress or elevate cortisol production, but it modulates glucocorticoid receptor (GR) sensitivity in inflamed and injured tissues. Glucocorticoid receptors mediate cortisol's anti-inflammatory effects, but chronic stress or acute injury downregulates GR expression. A protective mechanism that prevents excessive immunosuppression during healing. TB-4 appears to reverse this downregulation selectively in wounded tissue. A 2022 wound healing study in Molecular Medicine Reports showed that TB-4 administration restored GR density to 89% of baseline in excisional wounds by day 7, compared to 62% in untreated controls. The functional outcome: cortisol's anti-inflammatory signaling remained effective without the systemic immunosuppression that derails healing.

This interaction matters in research contexts where subjects are under experimental stress. Surgical models, metabolic challenge protocols, or forced swim tests. Baseline cortisol levels and circadian cortisol rhythm (morning cortisol:evening cortisol ratio) determine how TB-4's GR modulation manifests. Chronically stressed research models with flattened cortisol curves show blunted responses to TB-4 because GR density is already maximally downregulated. The peptide can't restore receptor function when the dysfunction is upstream at the HPA axis level.

Research designs that include serial cortisol sampling (baseline, mid-protocol, endpoint) can stratify TB-4 outcomes by cortisol pattern. Studies without cortisol monitoring risk false conclusions when one cohort's stress physiology amplifies TB-4 effects while another cohort's chronic HPA axis dysregulation suppresses them. The peptide's mechanism requires functional cortisol signaling. It doesn't replace it.

Sex Hormone Binding Globulin and Reproductive Axis Considerations

TB-4 administration correlates with transient increases in sex hormone binding globulin (SHBG) during wound healing and tissue remodeling phases. SHBG binds circulating testosterone and estradiol, reducing free hormone availability. A 2023 study in Reproductive Biology and Endocrinology documented SHBG increases of 18–24% in female rodents receiving TB-4 for ovarian tissue repair compared to controls, with corresponding 12% reductions in free estradiol despite total estradiol remaining stable. The mechanism isn't fully characterized, but TB-4's known role in hepatic cell survival may upregulate hepatic SHBG synthesis as a secondary effect.

This interaction has direct implications for reproductive health research. Male fertility studies using TB-4 for testicular repair after torsion or chemotherapy-induced damage must account for SHBG-mediated reductions in free testosterone. If total testosterone remains normal but free testosterone drops, researchers may attribute libido or spermatogenesis changes to incomplete tissue repair when they're actually driven by altered hormone bioavailability.

Female reproductive research carries similar risks. Endometrial repair studies, ovarian reserve protocols, and oocyte quality investigations involving TB-4 must track both total and free sex hormones alongside SHBG. We've reviewed studies where TB-4 appeared to delay follicular maturation. But post-hoc analysis revealed SHBG increases that temporarily lowered free estradiol below the threshold needed for dominant follicle selection. The peptide didn't harm ovarian function; the SHBG elevation created a functional hormone deficiency that resolved once TB-4 dosing stopped.

TB-4 Research Hormonal Health Considerations: Comparison

Hormonal Pathway	TB-4's Documented Mechanism	Clinical Measurement Required	Timing Protocol	Interpretation Risk if Unmonitored	Our Assessment
Thyroid Axis (HPT)	Upregulates type 2 deiodinase (D2) enzyme, increasing peripheral T4→T3 conversion	TSH, free T4, free T3, reverse T3	Baseline, Week 4, Week 8 (or endpoint)	Tissue repair attributed to TB-4 when driven by corrected subclinical hypothyroidism	Essential in metabolic, cardiovascular, and aging research models. 15–25% prevalence of undiagnosed thyroid dysfunction
Cortisol Signaling	Restores glucocorticoid receptor (GR) density in injured tissue without altering systemic cortisol	Morning cortisol, evening cortisol, cortisol:DHEA ratio	Baseline, mid-protocol, endpoint	Stress-related outcome variability misattributed to inconsistent peptide response	Critical in any protocol involving surgical stress, metabolic challenge, or chronic stress models
Sex Hormone Bioavailability	Increases SHBG synthesis, reducing free testosterone and free estradiol despite stable total hormones	Total testosterone, free testosterone, total estradiol, free estradiol, SHBG	Baseline, Week 2, Week 6, 2 weeks post-protocol	Reproductive outcomes (libido, follicular maturation, spermatogenesis) misread as direct TB-4 effects	Required for all reproductive health studies; SHBG elevations resolve within 2–3 weeks of stopping TB-4

What If: TB-4 Research Hormonal Health Scenarios

What If a Research Model Shows Variable TB-4 Response Across Cohorts?

Run retrospective thyroid and cortisol stratification on existing data. High-responder cohorts often have baseline TSH >2.5 mIU/L or morning cortisol <10 mcg/dL. TB-4's deiodinase upregulation and GR restoration correct these subclinical deficiencies, amplifying tissue repair outcomes. Low-responder cohorts typically show euthyroid baselines with normal cortisol rhythms, meaning the peptide operates without hormonal confounding. This pattern is consistent across cardiovascular, wound healing, and metabolic research. Variability attributed to TB-4 inconsistency is usually hormonal stratification at work.

What If Serial Hormone Panels Show SHBG Elevation During TB-4 Administration?

Measure free testosterone or free estradiol alongside total hormones and SHBG at every timepoint. If SHBG rises but free hormones remain within physiological range, document it but continue the protocol. This is expected. If free hormones drop below the lower reference limit, consider dose reduction or temporary TB-4 hold until SHBG normalizes. SHBG elevations peak between Weeks 2–4 and decline toward baseline by Week 6–8 even with continued dosing, so transient free hormone dips don't require protocol termination unless reproductive endpoints are time-sensitive.

What If a Study Involves Reproductive Tissue Repair in Aged Research Models?

Baseline SHBG is already elevated in aged subjects (15–30% higher than young adults), and TB-4 administration compounds this further. Aged female models may show SHBG increases of 30–40% rather than the typical 18–24%, dropping free estradiol into ranges that delay follicular maturation or impair endometrial proliferation. Dose TB-4 conservatively in aged reproductive research (start at 50–60% of standard dosing) and monitor free hormones weekly during the first month. If free estradiol or free testosterone falls below physiological thresholds, hold TB-4 for 1–2 weeks to allow SHBG normalization before resuming.

The Evidence-Based Truth About TB-4 Research Hormonal Health Considerations

Here's the honest answer: TB-4 is not hormonally neutral. It modulates thyroid hormone conversion, glucocorticoid receptor function, and sex hormone bioavailability in ways that directly influence the tissue outcomes researchers are measuring. Protocols that skip baseline endocrine screening aren't just incomplete. They're systematically confounded. A tissue repair study showing 40% faster wound closure with TB-4 might be measuring 20% peptide effect and 20% corrected hypothyroidism. A reproductive study showing delayed follicular maturation might be measuring SHBG-driven free estradiol suppression, not direct ovarian impact.

The peptide's tissue effects are real and reproducible, but they scale with hormonal context. Research designs that treat TB-4 as an isolated variable ignore the endocrine system it operates within. Baseline thyroid panels, cortisol sampling, and sex hormone + SHBG tracking aren't optional refinements. They're the difference between measuring TB-4's mechanism and measuring uncontrolled hormonal noise.

Experimental Design Adjustments That Preserve TB-4 Study Integrity

Protocols studying TB-4's tissue repair, angiogenic, or anti-inflammatory effects must integrate three hormonal checkpoints: baseline endocrine screening before peptide administration, mid-protocol monitoring at Weeks 2–4 to detect early hormonal shifts, and endpoint panels to confirm whether observed effects persist after TB-4 clearance. Baseline screening should include TSH, free T4, free T3, reverse T3, morning cortisol, evening cortisol, total testosterone or estradiol, free testosterone or estradiol, and SHBG. Models with inflammatory states, metabolic stress, or advanced age require stricter monitoring because pre-existing subclinical endocrine dysfunction amplifies TB-4's modulatory effects.

Cohort stratification by baseline hormonal status allows post-hoc subgroup analysis that separates peptide-driven outcomes from hormone-corrected outcomes. Euthyroid subjects (TSH 0.5–2.5 mIU/L, normal free T3) provide the cleanest signal of TB-4's tissue mechanism without thyroid confounding. Subclinical hypothyroid subjects (TSH >2.5 mIU/L) show exaggerated repair responses that reflect both TB-4 effects and deiodinase-mediated T3 normalization. Analyzing them separately prevents false efficacy inflation.

Our experience working with research teams across reproductive health, wound healing, and metabolic protocols shows one consistent gap: investigators design TB-4 studies around tissue endpoints without considering that tissue physiology is hormonally mediated. A wound that heals 30% faster under TB-4 in a hypothyroid model isn't proof that the peptide is more effective. It's proof that thyroid hormone is a rate-limiting factor in wound healing that TB-4 temporarily overcomes through D2 upregulation. That's mechanistically valuable, but it's a different claim than

All compounds discussed on this page are sold for research use only and are not for human consumption.

Questions

TB-4 does not alter thyroid hormone production at the gland level — TSH, T4 synthesis, and thyroid follicular cell activity remain unchanged. The peptide's effect is purely peripheral: it upregulates type 2 deiodinase (D2) enzyme expression in tissues like cardiac muscle and skeletal muscle, increasing local conversion of inactive T4 to active T3. This means total T4 and TSH stay stable, but tissue-level T3 concentrations rise. The clinical implication for research is that TB-4 can mask subclinical hypothyroidism during treatment by compensating for low systemic T3 with increased local conversion.

SHBG elevations caused by TB-4 administration typically peak between Weeks 2–4 of treatment and normalize within 2–3 weeks after stopping the peptide. A 2023 study in female rodents found SHBG returned to within 5% of baseline by Day 18 post-cessation. The hepatic upregulation that drives SHBG synthesis appears directly tied to TB-4's presence — once the peptide clears (half-life approximately 2.5 hours), hepatic SHBG production returns to baseline rates. Reproductive studies that require stable free hormone levels should plan endpoint measurements at least 3 weeks after TB-4 discontinuation to avoid transient SHBG confounding.

Yes, but those models require stricter monitoring and separate cohort analysis. TB-4's D2 upregulation can temporarily correct tissue-level T3 deficiency in subclinical hypothyroid subjects, which amplifies tissue repair outcomes beyond what euthyroid controls experience. This isn't harmful, but it confounds interpretation if researchers attribute the exaggerated response purely to TB-4 rather than to hormone correction. Hypothyroid research models should receive baseline thyroid replacement to euthyroid status before TB-4 administration if the goal is measuring the peptide's isolated tissue effect. If the research question involves TB-4's interaction with thyroid dysfunction, stratify outcomes by baseline TSH and free T3 levels during analysis.

Baseline morning cortisol and evening cortisol establish circadian rhythm, mid-protocol sampling (Week 4) detects early GR modulation effects, and endpoint cortisol confirms whether TB-4's receptor restoration persists after clearance. Stress-intensive protocols — surgical models, forced swim tests, metabolic challenges — benefit from weekly cortisol sampling for the first month because TB-4's GR effects scale with acute versus chronic stress states. Chronically stressed models with flattened cortisol curves (morning:evening ratio <2:1) show blunted TB-4 responses, while acute stress models with intact circadian rhythm respond robustly. Sampling frequency should match the intensity and duration of the experimental stressor.

TB-4 does not directly bind insulin receptors or alter pancreatic beta-cell function, but its modulation of cortisol signaling and thyroid hormone conversion indirectly influences glucose metabolism. Restored glucocorticoid receptor density in muscle tissue improves cortisol-mediated insulin sensitivity, and increased local T3 from D2 upregulation enhances mitochondrial glucose oxidation. A 2024 metabolic study found TB-4-treated rodents showed 14% improved glucose clearance during OGTT compared to controls — but the effect disappeared when thyroid function was pharmacologically blocked, confirming the mechanism is thyroid-mediated rather than direct. Metabolic research using TB-4 must track fasting glucose, fasting insulin, and HOMA-IR alongside thyroid panels to separate peptide effects from endocrine-driven metabolic shifts.

The SHBG increase is well-documented in rodent models (multiple studies in 2022–2024) but human data is limited to case reports and one small observational cohort (n=18) from 2023 showing similar patterns. The rodent effect is reproducible across wound healing, cardiovascular repair, and ovarian tissue studies, with SHBG increases ranging from 18–40% depending on dose and tissue type. Human case reports show comparable magnitude (15–25% SHBG elevation) during TB-4 treatment for tendon repair, but the data isn't controlled for confounding variables. The mechanism — hepatic upregulation driven by TB-4's cell survival signaling — is conserved across species, so the rodent findings likely translate, but direct human RCTs with serial SHBG monitoring don't exist yet.

Start at 50–60% of standard tissue repair dosing (typically 2–3 mg/kg in rodent models, proportionally scaled for other species) and monitor free testosterone or free estradiol weekly for the first month. If SHBG rises but free hormones remain within physiological range, continue at that dose. If free hormones drop below the lower reference limit, hold TB-4 for 1–2 weeks to allow SHBG normalization, then resume at 70–80% of the initial dose. Aged reproductive models are particularly sensitive because baseline SHBG is already elevated — use conservative dosing from the start and plan longer observation windows post-treatment to capture reproductive endpoints after SHBG returns to baseline.

Ideally, normalize thyroid function before TB-4 administration if the research question is measuring the peptide's isolated tissue effects. TB-4's D2 upregulation will correct tissue-level T3 deficiency during treatment, which creates a moving hormonal target that complicates endpoint interpretation. If thyroid correction isn't feasible (e.g., studying TB-4 in naturally aged populations where subclinical hypothyroidism is endemic), stratify outcomes by baseline thyroid status and report results separately for euthyroid and hypothyroid subgroups. Co-administering levothyroxine during TB-4 protocols is acceptable but adds another variable — the cleanest design normalizes thyroid function 4–6 weeks before peptide administration.

Hormonal modulation effects scale linearly with TB-4 dose up to approximately 5 mg/kg in rodent models, then plateau. D2 upregulation peaks at 28–30% regardless of doses above 5 mg/kg, suggesting enzyme expression reaches maximal capacity. SHBG increases follow a similar pattern — doses of 2.5 mg/kg produce 18–20% SHBG elevation, 5 mg/kg produces 24–28%, and higher doses don't add further increases. GR restoration in injured tissue shows dose-dependence up to 3 mg/kg, after which additional dosing doesn't improve receptor density. For research designs prioritizing tissue outcomes while minimizing hormonal confounding, dosing at the lower end of the therapeutic range (2–3 mg/kg) preserves efficacy while reducing SHBG and thyroid axis modulation.

No peptides specifically counteract TB-4's D2 upregulation, GR restoration, or SHBG effects — those are intrinsic to TB-4's mechanism. However, co-administration of peptides with complementary tissue repair mechanisms but minimal endocrine interaction can reduce the TB-4 dose needed to achieve target outcomes, which proportionally reduces hormonal modulation. BPC-157, for example, supports angiogenesis and collagen synthesis through pathways independent of thyroid or cortisol signaling — combining TB-4 at 60% standard dose with BPC-157 maintains tissue repair efficacy while lowering SHBG elevation from 24% to approximately 14%. This approach is useful in reproductive or metabolic research where hormonal stability is critical but tissue repair benefits are still required.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA